美敦力在印度推出适应性深部脑刺激系统用于帕金森病患者

New Delhi

新德里

, 23 April 2026

，2026年4月23日

: Medtronic, a global leader in healthcare technology, today announced the launch of its Adaptive Deep Brain Stimulation (aDBS) system, an innovation over conventional DBS, in India to further improve quality of life of patients living with Parkinson’s disease.

美敦力公司是全球医疗技术领域的领导者，今天宣布在印度推出其自适应深部脑刺激（aDBS）系统，这一创新超越了传统的DBS，将进一步改善帕金森病患者的生活质量。

The prevalence of Parkinson's disease (PD) in India is roughly 10% of the global burden, which is a considerable public health concern.

印度帕金森病（PD）的患病率约为全球负担的10%，这是一个相当大的公共卫生问题。

1

1

Parkinson’s is a progressive neurological condition that can affect how a person moves and functions in everyday life. Over time, it may make routine activities such as walking, writing, or holding everyday objects more difficult. While movement-related challenges are often the most visible, the condition can also influence other aspects of daily living, including communication, sleep, and overall well‑being.

帕金森病是一种渐进性神经系统疾病，可能影响一个人在日常生活中的行动和功能。随着时间的推移，它可能会使步行、书写或拿取日常物品等常规活动变得更加困难。虽然与运动相关的挑战往往最为明显，但这种疾病还可能影响日常生活的其他方面，包括沟通、睡眠和整体健康状况。

Today, a range of treatment approaches help manage symptoms as the disease evolves. Care is typically tailored over time, with treatment pathways adjusted based on individual needs and clinical assessment by specialists..

如今，一系列的治疗方法有助于在疾病进展过程中控制症状。护理通常是根据个人需求和专家的临床评估，随着时间的推移量身定制，并调整治疗路径。

2

2

Treatment options like Deep Brain Stimulation exist which involve manual adjustment of stimulation levels throughout the day, usually managed by patients or caregivers Medtronic’s aDBS technology is designed to adapt real time to changes in a patient’s condition or medication needs—helping deliver more consistent symptom management.

像深部脑刺激这样的治疗选项需要患者或护理人员手动调整一天中的刺激水平。美敦力的自适应深部脑刺激技术旨在实时适应患者病情或药物需求的变化，帮助实现更稳定的症状管理。

The aDBS system uses BrainSense™ technology, which has been approved by the U.S. Food and Drug Administration (FDA). .

aDBS系统使用了经美国食品药品监督管理局（FDA）批准的BrainSense™技术。

3-4

3-4

Adaptive deep brain stimulation (aDBS) is designed to automatically adjust therapy based on changes in brain signals or patient activity. By responding in real time, it aims to provide more consistent symptom control, minimize side effects, and help extend the life of the implanted device’s battery..

自适应深部脑刺激（aDBS）旨在根据脑信号或患者活动的变化自动调整治疗。通过实时响应，它力求提供更稳定的症状控制，减少副作用，并帮助延长植入设备电池的寿命。

With India expected to witness a significant rise in Parkinson’s disease cases—projected to become the second-highest globally within the next five years

预计印度将见证帕金森病病例的显著增加——预计在未来五年内成为全球第二高。

7

7

—the introduction of the aDBS system comes at a critical time. Although there is currently no cure for conditions such as Parkinson’s disease, deep brain stimulation (DBS) has been transforming the lives of patients with Parkinson’s and other neurological disorders for more than three decades.

——aDBS 系统的引入正值关键时期。尽管目前尚无治愈帕金森病等疾病的方法，但三十多年来，脑深部刺激 (DBS) 一直在改变帕金森病患者及其他神经系统疾病患者的生活。

5-6

5-6

DBS uses a small, pacemaker-like device, placed under the skin of the chest, to send electronic signals to an area in the brain that controls movement. To give you relief, these signals block some of the brain messages that cause the movement symptoms of Parkinson’s.

DBS 使用一个类似于起搏器的小型装置，放置在胸部皮肤下，向控制运动的大脑区域发送电子信号。为了缓解您的症状，这些信号会阻断一些导致帕金森病运动症状的大脑信息。

On the occasion,

在这种情况下，

Prateek Tiwari, Senior Director, Neuroscience & Specialty therapies, Medtronic India

普拉蒂克·蒂瓦里，高级总监，神经科学与专科治疗，美敦力印度

said, “

说：“

We are extremely proud to introduce this advanced technology in India, where Parkinson’s disease is an increasingly significant healthcare concern. Our mission has always been to alleviate pain, restore health, and extend life, and the introduction of this system reflects our continued commitment to that mission.

我们非常自豪地在印度推出这项先进技术，帕金森病在这里正成为一个日益重要的医疗问题。我们的使命始终是减轻痛苦、恢复健康并延长生命，而该系统的引入正体现了我们对该使命的持续承诺。

This milestone not only reaffirms our dedication to addressing the growing burden of Parkinson’s disease but also strengthens our leadership in bringing cutting-edge healthcare technologies to India to ultimately improve patients’ quality of life.

这一里程碑不仅重申了我们对解决帕金森病日益增加的负担的承诺，也巩固了我们在将尖端医疗技术引入印度以最终改善患者生活质量方面的领导地位。

.’’

.’’

As the burden of a disease such as Parkinson’s will rise, continued investment in cutting-edge technologies will be essential to expanding access to better care, supporting clinicians with deeper insights, and ultimately improving the quality of life for patients across the country.

随着帕金森病等疾病的负担增加，持续投资于尖端技术将对扩大优质护理的可及性、为临床医生提供更深入的见解，以及最终改善全国患者的生活质量至关重要。

Patients considering deep brain stimulation (DBS) typically begin by consulting a Movement Disorder Specialist, usually a neurologist, who evaluates whether their condition may benefit from this therapy. DBS follows a coordinated, team-based approach, with patients often referred to a comprehensive DBS clinic or neurosurgery board for further assessment.

考虑进行脑深部刺激（DBS）的患者通常首先会咨询运动障碍专科医生，通常是神经科医生，由其评估他们的病情是否可能从这种治疗中受益。DBS 采用协调的团队合作方法，患者通常会被转诊到综合 DBS 诊所或神经外科委员会进行进一步评估。

If considered suitable, a Functional Neurosurgeon—specially trained to perform the procedure—works alongside the care team to implant and program the device..

如果认为合适，经过专门培训执行该手术的功能神经外科医生将与护理团队合作，植入并编程该设备。

For further information, please contact:

如需更多信息，请联系：

Medtronic

美敦力

Nidhi Acharya

尼迪·阿查里亚

nidhi.acharya@medtronic.com

尼迪·阿查里亚@美敦力.康姆

All information contained herein is for general awareness purposes only, and nothing contained herein should be construed as medical advice or recommendation. Patients should consult their physician to discuss their conditions and seek relevant medical advice.

本文包含的所有信息仅用于一般性了解目的，此处包含的任何内容均不应被解释为医疗建议或推荐。患者应咨询医生以讨论其病情并寻求相关医疗建议。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更果敢的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找并发现解决方案，勇敢地应对人类面临的最严峻的健康问题。我们的使命——减轻病痛、恢复健康、延长生命——团结了遍布150多个国家的95,000多名充满热情的员工。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和治疗手段涵盖70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多元化的知识、无尽的好奇心和帮助所有有需要的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

期待我们带来更多成果，因为我们致力于推动以洞察力为基础的护理、以人为本的体验，以及为我们的世界创造更好的结果。在我们所做的一切中，我们正在创造非凡的工程。欲了解有关美敦力的更多信息，请访问。

www.Medtronic.com

www.美敦力.com

and follow

跟随

Medtronic

美敦力

on

在

LinkedIn

领英

.

。

References

参考文献

1

1

https://pubmed.ncbi.nlm.nih.gov/40171552/#:~:text=Abstract,services%2C%20and%20tertiary%20care%20hospitals

https://pubmed.ncbi.nlm.nih.gov/40171552/#:~:text=摘要，服务，以及三级护理医院

.

。

2

2

https://www.medtronic.com/sg-en/patients/conditions/about-parkinsons-disease.html

https://www.medtronic.com/sg-en/patients/conditions/about-parkinsons-disease.html

3

3

Rosa M, Arlotti M, Marceglia S, et al. Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients. Mov Disord 2017;32(4):628–9.

Rosa M, Arlotti M, Marceglia S, 等。自适应深部脑刺激控制帕金森病患者左旋多巴诱导的副作用。《运动障碍》2017;32(4):628–9。

4.

4.

Pina-Fuentes D, Dijk JMC van, Zijl JC van, et al. Acute effects of adaptive Deep Brain Stimulation in Parkinson’s disease. Brain Stimul 2020;13(6):1507–16.

Pina-Fuentes D, Dijk JMC van, Zijl JC van, 等。自适应深部脑刺激在帕金森病中的急性效应。《脑刺激》2020;13(6):1507–16。

5.

5.

Little S, Pogosyan A, Neal S, et al. Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol 2013;74(3):449–57.

Little S, Pogosyan A, Neal S, 等。晚期帕金森病的自适应深部脑刺激。《神经学年鉴》2013；74（3）：449-57。

6.

6.

Little S, Tripoliti E, Beudel M, et al. Adaptive deep brain stimulation for Parkinson’s disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting. J Neurol Neurosurg Psychiatry 2016;87(12):1388–9.

Little S, Tripoliti E, Beudel M, 等。自适应深部脑刺激治疗帕金森病在急性环境下显示出比传统刺激更少的言语副作用。《神经病学、神经外科与精神病学杂志》2016；87（12）：1388-9。

7

7

https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/india-expected-to-see-surge-in-parkinsons-disease-becoming-2nd-highest-in-5-yrs-experts-at-6th-international-annual-symposium-2026-in-kerala/articleshow/128076658.cms?from=mdr

https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/预计印度将出现帕金森病激增-在5年内成为第二高-专家于2026年第六届国际年度研讨会在喀拉拉邦/articleshow/128076658.cms?from=mdr